Abstract▴ Pregabalin, the pharmacologically active S-enantiomerof 3-aminomethyl-5-methyl-
hexanoic acid, has a similar pharmacological profile to that of its developmental …

Objectives: This study used a randomized withdrawal design to evaluate the efficacy of
pregabalin versus placebo for pain relief in patients with painful diabetic peripheral …

Seven published, randomized, placebo-controlled clinical trials with pregabalin have shown
robust efficacy for relief of neuropathic pain from DPN and PHN. An investigation of the …

Objectives: This randomized, double-blind, placebo-controlled, multicenter, 2-period
crossover study (two 6-week treatment periods separated by a 2-week washout period) …

Diabet. Med. 28, 109–116 (2011) Abstract Aims To evaluate the efficacy, safety and
pharmacokinetics of pregabalin in treating neuropathic pain associated with diabetic …

Objective: Pregabalin, an alpha2-delta ligand with analgesic, anxiolytic, and anticonvulsant
activity, has been evaluated for treatment of neuropathic pain. The authors assessed the …

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, 8-week trial
(with subsequent open-label phase) evaluated the effectiveness of pregabalin in alleviating …

This was a 6-week, randomized, double-blind, multicenter study evaluating the efficacy of
pregabalin in the treatment of painful diabetic neuropathy. Two hundred forty-six men and …

Objectives: To evaluate pregabalin's efficacy and safety versus placebo to reduce pain in
patients with diabetic peripheral neuropathy (DPN) using a concomitant nonsteroidal anti …

OBJECTIVE—To evaluate the efficacy, safety, and tolerability of pregabalin across the
effective dosing range, to determine differences in the efficacy of three times daily (TID) …